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Mutations in the heat-shock 
protein A9 (HSPA9) gene cause 
the EVEN-PLUS syndrome of 
congenital malformations and 
skeletal dysplasia
Beryl Royer-Bertrand1,2, Silvia Castillo-Taucher3, Rodrigo Moreno-Salinas4, Tae-Joon Cho5, 
Jong-Hee Chae6, Murim Choi7, Ok-Hwa Kim8, Esra Dikoglu2, Belinda Campos-Xavier2, 
Enrico Girardi9, Giulio Superti-Furga9, Luisa Bonafé2, Carlo Rivolta1, Sheila Unger10 & 
Andrea Superti-Furga2,11
We and others have reported mutations in LONP1, a gene coding for a mitochondrial chaperone 
and protease, as the cause of the human CODAS (cerebral, ocular, dental, auricular and skeletal) 
syndrome (MIM 600373). Here, we delineate a similar but distinct condition that shares the 
epiphyseal, vertebral and ocular changes of CODAS but also included severe microtia, nasal 
hypoplasia, and other malformations, and for which we propose the name of EVEN-PLUS syndrome 
for epiphyseal, vertebral, ear, nose, plus associated findings. In three individuals from two families, 
no mutation in LONP1 was found; instead, we found biallelic mutations in HSPA9, the gene that 
codes for mHSP70/mortalin, another highly conserved mitochondrial chaperone protein essential in 
mitochondrial protein import, folding, and degradation. The functional relationship between LONP1 
and HSPA9 in mitochondrial protein chaperoning and the overlapping phenotypes of CODAS and 
EVEN-PLUS delineate a family of “mitochondrial chaperonopathies” and point to an unexplored role 
of mitochondrial chaperones in human embryonic morphogenesis.
Recently, we and others reported on the identification of mutations in LONP1 as the cause of the human 
genetic disorder, CODAS (cerebral, ocular, dental, auricular and skeletal) syndrome (MIM 600373)1,2. 
LONP1 codes for a phylogenetically conserved protein of the mitochondrial matrix that has both 
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chaperone and protease activity. Subsequently, we have identified patients with a condition that shares 
the skeletal features of the CODAS syndrome but includes a distinct craniofacial dysmorphism and car-
diac and intestinal malformations.
A review of the literature suggests that one sporadic patient reported as having CODAS3, two sibs 
reported as having an EVE (epiphyseal-vertebral-ear) syndrome4, and a further sporadic patient reported 
as having caudal regression with anal atresia and spondylo-epiphyseal dysplasia5 may have had the disor-
der we describe here, for which we propose the name of EVEN-PLUS syndrome for epiphyseal, vertebral, 
ear, nose, plus associated findings.
We report here the identification of recessive mutations in the HSPA9 gene in our three patients 
with this syndrome. The HSPA9 gene codes for a mitochondrial chaperone that has been implicated 
in different physiologic processes, and thus has been known under several different names (heat-shock 
70 kda protein 9 (HSPA9, HSPA9B), mortalin and mortalin 2 (MOT/MOT2), 75 KDa glucose-regulated 
protein (GRP75), among others)6–8. Notably, the HSPA9 protein participates in, and is necessary for, the 
proteolytic activity of LONP19–12.
Clinical Reports
Patient 1. This girl was the first child of a non-consanguineous couple of Korean origin. Upon specific 
questioning, there was no history of Parkinson disease in parents or grandparents. She was born at term 
(39 weeks) with a length of 38 cm and a weight of 2.2 kg. Her face showed midface hypoplasia with mark-
edly hypoplastic nasal bones, giving her a flat nose with nares that were triangular in shape (Fig. 1). She 
had arched eyebrows and synophrys. Her external ears were markedly small and poorly formed (Fig. 1), 
while the ear canal was present. She was noted to have anal atresia that was subsequently surgically cor-
rected. An atrioseptal defect (ASD) was present at birth but repeat ultrasound at age 20 months showed 
that it had closed spontaneously. At age 16 months, her developmental quotient was approximately 80; a 
cerebral MRI was normal, an abdominal ultrasound examination did not show abnormalities of kidneys 
or urinary tract, an ophthalmologic examination was normal (specifically, no cataracts were observed), 
and a CGH array study gave normal results. Skeletal radiographs obtained at age 16 months at 4 yrs 
showed lateral vertebral clefts, dysplasia of the proximal femurs and acetabula, “bifid” distal femurs and 
marked epiphyseal dysplasia at her knees (Fig.  2). These skeletal changes were considered typical of 
CODAS syndrome. However, no variants in the LONP1 gene were found.
Patient 2. This girl was born to a consanguineous couple of Chilean origin; the parents are uncle once 
removed and niece. Family history was negative for Parkinson disease. Short long bones were noted pre-
natally. She was born at 38 weeks’ gestation with a length of 39 cm (markedly below the 3rd percentile), a 
Figure 1. Photographs of patients 1 (A,B), 2 (C,D) and 3 (E,F). Common features include hypoplasia of 
the midface and of the nasal bones giving a flat nose, triangular nares, arched eyebrows with synophrys, 
and hypoplastic-dysplastic external ears. Panel G and H show the flat nose with triangular nares in patients 
3 and 2, respectively, with a single central incisor in patient 3; and panel I shows the lesion of congenital 
aplasia cutis on the vertex of patient 3.
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weight of 2.8 kg, and a head circumference of 33,5 cm (slightly below the 10th percentile). Her karyotype 
was normal in blood cells. When seen in the genetics clinic at age 5 years, her weight was 12,5 kg, and 
she had severe short stature (markedly below the 3rd percentile for Chilean children) with a height of 
80 cm; her head circumference 47,8 cm (below the 3rd percentile). She had severe bilateral microtia with 
apparently normal external ear duct, arched eyebrows with mild synophris, and a very flat nose with 
nares that were triangular in shape (Fig. 1). Her cranial fontanels were still open, she had two lateral hair 
whorls and a small area of aplasia cutis on her cranium. Her limbs looked short. An echocardiography 
showed a small ASD. Cerebral, abdominal and renal ultrasound scans gave normal results. Her language 
development was appropriate and she attended kindergarten. Radiographic findings at birth included 
dysplasia of the femoral heads and of the acetabulum as well as “bifid” distal femurs (Fig. 2). At age 5 
yrs, the proximal femoral epiphyses were not ossified, the femoral heads appeared to be dislocated, and 
the epiphyses at the knee were dysplastic.
Patient 3. This girl is the younger sister of patient 2. Oligohydramnios and short long bones were 
noted prenatally. Born after 38 weeks of gestation, she was very short at birth, while weight and head 
circumference were at the lower limit of normal (weight, 2.7 kg; length, 39 cm; and head circumference, 
34,5 cm); clinically, she appeared to have short limbs. She also had rectal atresia without fistula that 
required a surgical colostomy. She had a normal female karyotype in blood cells. At age 8 months, 
developmental delay was diagnosed. An echocardiography done at age 2 years 6 months showed per-
sistent foramen ovale and aneurysmatic septum. When she was seen in the genetics clinics at age 3 
years 6 months, her weight was 12 kg and her height 79 cm (both below the 3rd percentile). She had 
brachycephaly, severe bilateral microtia (Fig.  1) with apparently normal ear canal, aplasia cutis on the 
skull vertex, a very flat nose with triangular nares, arched eyebrows with mild synophrys, high palate, 
hypodontia (Fig.  1), short neck, and imperforate anus. She was developmentally delayed and attended 
a specialized Teleton institution. Imaging studies showed right vesico-ureteral reflux with right kidney 
nephropathy. A brain CT showed dysgenesis of the corpus callosum. Skeletal-radiographic findings are 
shown in Fig.  2. Radiographic findings were similar to those seen in her sister and included vertebral 
coronal clefts (Fig. 2) and agenesis of the coccyx.
Figure 2. Skeletal-radiographic features. Panels A and B: patient 2 at birth (A) and at age 5 years (B) 
showing underossified pubic bones; bilateral dysplasia of the femoral heads at birth resulting in hip 
dislocation at age 5 yrs; and a “bifid” appearance of the distal femur with epiphyseal delay at birth, with 
dysplastic epiphyses that are “socketed” in the bifid femur at age 5 yrs; and small, laterally dislocated patellae. 
Panels C, D and E: Patient 1 at birth (C) with dysplastic femoral heads and at age 4 years (D,E) showing 
the bifid distal femur and the markedly dysplastic distal femoral epiphyses. The proximal tibial epiphyses 
are too small but less severely affected. Panels F and G: lateral lumbar spine of patient 3 at age 3 yrs (F) 
and of patient 1 at age 4 yrs (G) showing remnants of coronal clefts of the vertebral bodies. The clefts are 
prominent at birth and gradually disappear as ossification progresses.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:17154 | DOI: 10.1038/srep17154
Results
Exome sequencing identifies low-frequency mutations in the HSPA9 gene in individuals 
with the EVEN-PLUS syndrome. The sequential analysis of the variants identified in the exomic 
sequence of the patients is presented in table S1. Variants were filtered for non-synonymy, for rarity, and 
for quality. Subsequently, genes were scored for the presence of either two variants at heterozygosity, or 
one or more variants at homozygosity, in the affected sibs as well as in the sporadic patient. There was 
only one gene that fit all criteria, namely, HSPA9. Patient 1 was found to be heterozygous for variants 
c.383A > G (p.Y128C) and c.882_883delAG (p.V296*). Patients 2 and 3 were found to be homozygous 
for variant c.376C > T (p.R126W). Both R126 and Y128 are extremely conserved (supplementary Figure S1). 
Results of prediction software PolyPhen-213 and Provean14 suggested damaging results on protein struc-
ture (Fig.  3). The V296* truncation mutation abolishes more than half of the protein, including all of 
the substrate binding domain (Fig.  3); however, the premature termination codon is likely to promote 
nonsense-mediated decay. All mutations were confirmed by direct bidirectional Sanger sequencing of 
a second batch of genomic DNA; heterozygosity was confirmed in the unaffected parents. All three 
mutations were present at extremely low frequency in the ExAC browser (exac.broadinstitute.org/gene/
ENSG00000113013) and were absent from the Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
(Fig. 3). These frequencies are compatible with recessive inheritance of a rare disorder. Interestingly, the 
R126W mutation had been observed at heterozygosity in one individual out of three cohorts comprising 
over 1500 adult patients with Parkinson disease, and databases are since annotated with a possible role 
of this mutation in Parkinson disease15,16 (but see discussion below).
3D molecular modeling of HSPA9 and mapping of the affected amino acid residues. Mapping 
of the mutated amino acids on the available HSPA9 nucleotide binding domain structure (NBD)17 
revealed that both R126W and Y128C are located next to each other on the surface of the protein, at 
some distance from the ATP/ADP binding site (Fig. 4A). Moreover, in our model the two mutations lie 
on a loop close to the predicted interface between the NBD and the substrate binding domain (SBD, 
Fig. 4B).
Discussion
Clinical delineation of the EVEN-PLUS syndrome. The identification of LONP1 mutations in the 
CODAS syndrome allowed for the recognition of its wide phenotypic spectrum1,2. Subsequently, gene-based 
phenotypic sorting allowed us to identify a CODAS-related phenotype that is not associated with LONP1 
mutations. This syndrome shares the skeletal features of the CODAS syndrome (vertebral and epiphyseal 
changes as shown in Fig. 2) but is further characterized by prenatal-onset short stature, a distinct cranio-
facial phenotype with microtia, a flat facial profile with flat nose and triangular nares, cardiac malforma-
tions, and other findings such as anal atresia, hypodontia, aplasia cutis, and others (see Fig. 1 and Table 1). 
Examples of this syndrome seem to have been previously reported: in 1990, Kozlowski et al. described a 
six-year-old boy, with « caudal regression and spondylo-epiphyseal dysplasia »5. The flat nose, dysplastic 
ears, and the combination of rectal and bladder incontinence with sacral agenesis observed in that boy are 
Figure 3. Scheme of the HSPA9 protein showing the localization of the mutations observed. The HSPA9 
(mortalin) protein has a short mitochondrial import sequence and two main domains, the nucleotide 
(ATP/ADP) binding domain and the substrate binding domain (Dores-Silva et al., 2015). The two amino 
acid substitution affect the nucleotide binding domain; the truncation mutation predicts the loss of part 
of the nucleotide binding domain and all of the substrate binding domain (unless the mRNA undergoes 
nonsense-mediated decay; see Results). The lower part shows a summary of the pathogenicity prediction 
software (PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/) and PROVEAN, http://provean.jcvi.org/index.
php) as well as the allelic frequencies in the ExAC project (exac.broadinstitute.org/gene/ENSG00000113013).
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reminiscent those in our patients; the radiographic changes, namely, vertebral clefts, severe epiphyseal dys-
plasia, “bifid” appearance of the distal femur, and coccygeal agenesis, are virtually identical (see Fig. 2). In 
2009, Marlin et al. reported on a boy diagnosed as having CODAS3; however, while the facial features in the 
CODAS syndrome are non-specific, the craniofacial features and the skeletal findings of that patient closely 
match those observed in our patients. Finally, Amiel and coworkers had reported, in 1994, two sisters who 
had epiphyseal and vertebral dysplasia in combination with dysplastic external ears; they discussed CODAS 
as a possible diagnosis but concluded that those sisters probably represented a separate disorder for which 
they coined the name of EVE (epiphyses, vertebrae, ear) syndrome4. Although no DNA could be obtained 
from these individuals to test for the presence of HSPA9 mutations, the clinical resemblance and similar-
ity of radiographic features strongly suggest that these four patients had the same disorder as the one we 
Figure 4. Localization of the mutations observed on the HSPA9 protein structure. (A) Mapping of the 
R126W and Y128C mutation of the crystal structure of the NBD (light blue). Both mutations lie on the 
surface of the protein, opposite to the nucleotide binding site. R126W is shown in red, Y128C in yellow. 
(B) Localization of the mutations in relation to the NBD/SBD interface (NBD and SBD shown in light green 
and purple respectively) in a model of the full length protein. Only a portion of the SBD is shown for clarity. 
Both mutations are located on a single loop near the interface, as shown in detail in the inset.
Pat. 1 Pat. 2 Pat. 3
birth measurements
length 38 cm, weight 
2.2 kg (at week 39); both 
values markedly below the 
normal range
length 39 cm, weight 2.8 kg (at week 
38); length markedly below the normal 
range
length 39 cm, weight 2750 g (at 
week 38); length markedly below 
the normal range
nose
hypoplastic nose with 
vertical groove on tip 
(bifid tip) and triangular 
nares
hypoplastic nose with vertical groove 
on tip (bifid tip) and triangular nares
hypoplastic nose with vertical 
groove on tip (bifid tip) and 
triangular nares
ears absent external ears (anotia), open ear duct severe microtia with absent upper helix
absent external ears with open ear 
duct; possible hypoacusis
eyes synophrys; no cataract synophrys; no cataract synophrys; no cataract
teeth single upper central incisor, absence of some lateral incisors
skin atopic dermatitis, sparse hair
two lateral hair whorls and area of 
aplasia cutis on the skull vertex
area of aplasia cutis on the skull 
vertex
heart ASD (spontaneously closed at age 20 mos) ASD (ostium secundum)
patent foramen ovale and 
aneurysmatic septum
gastrointestinal anal atresia normal abdominal ultrasonography anal atresia
kidney/urogenital No abnormalities on ultrasound
1 UTI at 1 year but normal renal 
ultrasonography
vesicoureteral reflux, hypoplastic 
right kidney
brain normal MRI at age 5 mos normal cerebral ultrasonography agenesis of the corpus callosum with separated frontal horns
psychomotor development Borderline-normal Normal evaluation at kindergarten level, including language Moderate developmental delay
HSPA9 mutations p.Y128C/p.V296* pR126W/p.R126W pR126W/p.R126W
Table 1.  Synopsis of clinical features in the three individuals with EVEN-PLUS syndrome and HSPA9 
mutations.
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describe here. Thus, we propose to retain the name suggested by Amiel and coworkers and to change it to 
“EVEN-PLUS syndrome” (for epiphyses, vertebrae, ears and nose, plus associated findings), reflecting the 
main clinical findings of the syndrome. While the skeletal findings in EVEN-PLUS are shared with CODAS, 
the facial features and the presence of associated malformations are distinct to the EVEN-PLUS syndrome.
Recessive mutations in the HSPA9 gene are the basis of the EVEN-PLUS syndrome. Several 
lines of evidence support the causative role of the HSPA9 mutations in the pathogenesis of this complex 
malformation syndrome. The genetic evidence consists in the rarity or absence of the variants in our 
in-house population (to exclude systemic technical errors) and in publicly available databases (ExAC, 
EVS); their presence at compound heterozygosity in patient 1 (non-consanguineous parents) as well as in 
homozygosity in patients 2 and 3 (consanguineous parents); the phylogenetic conservation of the affected 
residues (supplementary Figure 1); as well as the consequences at the protein level both for the premature 
stop codon mutation predicting the loss of more than half of the protein, and for the amino acid substi-
tutions predicted in silico to be damaging (Fig. 3). The R126W and Y128C mutations are located on the 
NDB but are unlikely to directly affect this activity, due to their distance from the active site. However, 
the proximity of the mutation sites to the predicted NBD/SBD interface could result in the disruption 
of this interaction, thereby affecting the function of the protein. Interestingly, our 3D model of HSPA9/
mortalin is consistent with a recent in solution analysis of the HSPA9 structure6, which places the NBD/
SBD interface in similar orientation as the one predicted in our own molecular model. It seems therefore 
likely that the R126W and Y128C mutations result in similar consequences as the ones expected from the 
V296* mutation, which, if the mRNA escapes nonsense-mediated decay, abolishes the NBD/SBD inter-
face and the whole substrate binding domain. Finally, albeit in another context, the R126W substitution 
has been shown to have adverse effects on HSPA9 protein function (see below).
HSPA9/mortalin, a protein with (too) many functions? The product of the HSPA9 gene, a 70 kDa 
heat-shock protein, has been extensively studied in the past 25 years and yielded precious insights on 
mitochondrial protein import and folding6–8,10. It is associated principally with the mitochondrial matrix 
but can be found in the cytoplasm as well as in the nucleus. Its main role is that of a chaperone that 
participates in the import of proteins from the cytosol to the mitochondrial matrix as well as their fold-
ing18,19. As a heat-shock protein with ATPase activity, it prevents the accumulation of unfolded, dysfunc-
tional proteins20. Because of its different localizations and multiple binding partners, the HSPA9 protein 
has been known under several different names (mHSP70, mortalin, mot-2, GRP75) and has been asso-
ciated with a large number of different processes ranging senescence to immortalization, oncogenesis, 
neurodegeneration, protection from oxidative stress, hematopoiesis, and even viral replication, among 
others6,7. Some of these studies, done in different contexts, have produced results that are relevant to our 
results. In 2005, Craven et al. studied a zebrafish mutant, crimsonless, ascertained for ineffective hemato-
poiesis. They identified a single amino acid substitution, G492E, in the HSPA9b gene (the zebrafish 
homologue of human HSPA9) as responsible for this phenotype. A morpholino knock-down model of 
HSPA9b effectively reproduced the crimsonless phenotype21. Although the study was focused on hemato-
poiesis, it was noted that the head and eyes appeared stunted as early as 38 hpf21; moreover, after 48 hpf 
all development appeared to halt, including further maturation of the musculature, fins, and internal 
organs, and the animals died around 72 hpf21, indicating that HSPA9b knockdown had more widespread 
effects on embryonic development. Other investigators have investigated a possible role of HSPA9 in the 
pathogenesis of Parkinson disease, based on the physical and functional relationship of HSPA9 (often 
referred to as mortalin in that literature) with parkins. In two studies on the possible role of genetic 
variations in HSPA9 in the pathogenesis of Parkinson disease, the R126W mutation has been identified 
at heterozygosity in 1 of 330 Spanish patients16, and subsequently in 0 (none) of two cohorts of 286 and 
1008 German patients15. In spite of the questionable statistical significance of this observation, expression 
studies using wild type and mutated HSPA9 were done, showing that the R126W mutation does impact 
the function of the HSPA9 protein measured by its effects on mitochondrial morphology, mitochondrial 
membrane potential, the production of reactive oxygen species15,22 and the cell sensitivity to exogenous 
oxidative stress22. These expression studies confirm that the R126W mutation is not a neutral polymor-
phism but does impair HSPA9 function, in accordance with in silico predictions and 3D mapping data.
LONP1 mutations in the CODAS syndrome and HSPA9 mutations in the EVEN-PLUS syn-
drome suggest the existence of a family of “mitochondrial chaperonopathies”. The concept 
of families of phenotypes coming from genes in the same pathway, or related by a common function 
(such as the cohesinopathies, or the cholesterol biosynthesis defects, or the mucopolysaccharidoses) is 
well established. While the identification of mutations in a mitochondrial matrix protease (LONP1) in 
patients with the CODAS syndrome was unexpected1,2, the identification of mutations in a related gene 
(HSPA9) in EVEN-PLUS syndrome confirms the previous studies and suggests a common pathogenesis 
of the two syndromes. In fact, the functional relationship between HSPA9 and LONP1 in the mitochon-
drial chaperone-protease network9,10,23 and the phenotypic overlap between CODAS and EVEN-PLUS 
syndromes delineate a new family of disorders – the “mitochondrial chaperonopathies”.
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Mechanistic pathogenesis of the EVEN-PLUS and CODAS syndrome remains unclear but is 
likely to be different than that of classic mitochondriopathies. In spite of the numerous stud-
ies on HSPA9 function, and of the studies of Strauss et al. on LONP1 mutations found in the CODAS 
syndrome1, the pathogenesis of the developmental defects associated with LONP1 and HSPA9 mutations 
remain unexplained. The phenotype of the CODAS syndrome, and even more so that of EVEN-PLUS, 
do not resemble those of other multisystem mitochondrial diseases; there is no indication of the “energy 
failure” process that is central to the pathogenesis of prototypical mitochondrial disorders such as the 
Pearson, Kerns-Sayre, MELAS, MERFF, or Alpers syndromes (reviewed by Andreux et al., 201324). 
Recessive mutations in a different mitochondrial chaperone-protease, CLPP, have been identified as one 
cause of the Perrault syndrome of ovarian failure and hearing loss, a condition that more closely resem-
bles the classic mitochondriopathies25. Many of the clinical features of EVEN-PLUS syndrome (micro-
tia, small nose, abnormal hair patterns, anal atresia, sacral agenesis) are the consequence of disturbed 
embryonic morphogenesis. But how can HSPA9 malfunction result in dysmorphogenesis? Heat-shock 
genes are widely expressed in vertebrate development even in absence of stress factors, suggesting a 
role in development26. Specifically, HSPA9 is known to interact with FGF127 as well as with Smad2, 
decreasing TGF-b signal transduction and affecting epithelial-mesenchymal transition28. Studies of the 
possible roles of HSPA9 in embryonic development may give an explanation for the defects observed in 
the EVEN-PLUS syndrome.
Awareness about the EVEN-PLUS syndrome and availability of molecular diagnosis will allow to rec-
ognize further cases, to increase our knowledge on the phenotypic spectrum associated with mutations 
in HSPA9, and to learn about the long-term outcome of affected individuals. The wealth on publications 
on the multiple roles of HSPA9/mortalin/mHSP70 notwithstanding, only these clinical observations may 
give us in vivo indications on the essential and non-essential roles of HSPA9 in prenatal development as 
well as over the entire human life-span.
Methods
The study was done in accordance with regulations for studies on human subjects of the hospitals in 
Lausanne, Seoul, and Rancagua. In addition, approvals from the IRB of the Seoul National Hospital, and 
of the Ethics Commission of the Lausanne University Hospital, were obtained. Peripheral blood was 
obtained with informed consent from the patients and their parents and genomic DNA was extracted 
by routine methods. Fragmented genomic DNA was purified with AMPure XP beads and the quality 
of the fragmented DNA was assessed with an Agilent Bioanalyzer. Preparation of the exome enriched, 
barcoded sequencing libraries was perfomed using Agilent SureSelect Human All Exon v4 kit. The final 
libraries were quantified with a Qubit Fluorometer (Life Technologies) and the correct size distribution 
was validated with an Agilent Bioanalyzer. Libraries were sequenced on Illumina HiSeq 2000, generating 
100 bp paired-end reads. Raw reads were aligned onto the hg19 reference genome with Novoalign (http://
www.novocraft.com) and the data cleanup and variant calling were performed according to GATK Best 
Practices recommendations29. Variant filtering was made with Annovar30 and with own perl and bash 
scripts (available on request). Variants identified by this procedure were verified by direct PCR ampli-
fication of target exons from genomic DNA and bidirectional Sanger sequencing. A molecular model 
for the full-length human HSPA9 protein was generated with I-TASSER31. Figures were generated in the 
PyMOL Molecular Graphics System, Version 1.7.4 (Schrödinger, LLC ).
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